APEIRON Biologics AG, based in Vienna, Austria, is a clinical stage biotech company developing innovative products in cancer immunotherapy. The company was founded by Professor Josef Penninger and became operational in 2006. Apeiron currently employs about 45 people and is led by a management team with strong background in the biotech industry and drug development, especially in immuno-oncology.

Apeiron’s impressive track record in R&D of innovative projects has been validated by several license deals with Pharmaceutical companies (GSK for APN01, Sanofi for APN411, EUSA Pharma for APN311) and importantly by the marketing authorization in the EU for APN311 in May 2017 (dinutuximab beta; Qarziba®). APN311 is a monoclonal antibody for immunotherapy of pediatric neuroblastoma, a rare and severe childhood cancer.
See projects for the present status of Apeiron's portfolio projects.

 Non-Confidential Company Presentation

  • 129 hits28 August 2018

    APEIRON Expands Executive Board and Appoints Dr. Anderson Gaweco as Chief Medical and Scientific Officer (CMSO)

    Dr. Gaweco will lead APEIRON’s rapidly advancing immuno-oncology programs and oversee the discovery, clinical and medical functions of the Company’s growing new molecular entities pipeline of innovative cancer immunotherapies.

     Press Release